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Abstract
Background: Carbon ion radiotherapy (CIRT) has been delivered to more than 20,000 patients worldwide.
International trials have been recommended in order to emphasize the actual benefits. The ULICE program
(Union of Light Ion Centers in Europe) addressed the need for harmonization of CIRT practices. A comparative
knowledge of the sources and magnitudes of uncertainties altering dose distribution and clinical effects during the
whole CIRT procedure is required in that aim.
Methods: As part of ULICE WP2 task group, we sent a centrally reviewed questionnaire exploring candidate sources of
uncertainties in dose deposition to the ten CIRT facilities in operation by February 2017. We aimed to explore native
beam characterization, immobilization, anatomic data acquisition, target volumes and organs at risks delineation,
treatment planning, dose delivery, quality assurance prior and during treatment. The responders had to consider the
clinical case of a clival chordoma eligible for postoperative CIRT according to their clinical practice. With the results, our
task group discussed ways to harmonize CIRT practices.
Results: We received 5 surveys from facilities that have treated 77% of the patients worldwide per November 2017. We
pointed out the singularity of the facilities and beam delivery systems, a divergent definition of target volumes, the
multiplicity of TPS and equieffective dose calculation approximations.
Conclusion: Multiple uncertainties affect equieffective dose definition, deposition and calculation in CIRT. Although it
is not possible to harmonize all the steps of the CIRT planning between the centers, our working group proposed
counter-measures addressing the improvable limitations.
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Highlights
 CIRT should be reported similarly to initiate
international trials
 Different uncertainties affect dose-effect relationship
throughout CIRT planning
 Equieffective dose and target volume definition and
application require particular attention
 We propose some suggestions to harmonize the
practices
Background
Carbon ions are densely ionizing particles with a higher
relative biological effectiveness (RBE) and physical se-
lectivity compared to photons [1, 2].
Carbon-ion radiation therapy (CIRT) is available in
10 centers worldwide [3]. While Japanese centers have
studied a broad spectrum of indications with dose es-
calation trials, hypofractionation and passive beam
shaping (PS), the German facilities have treated
smaller but homogeneous cohorts, developed fully ac-
tive beam shaping (ABS), and a specific mapping of
RBE-weighted dose. Per end of 2017, more than
20,000 patients have been treated worldwide with
CIRT, mainly in phase I-II trials [4–7].
Due to the technical and financial investments required
to expand CIRT, the decisions-makers are requesting
phase III studies. These trials are particularly complex to
lead in CIRT due to the rarity of indications and available
resources, but also due to the different practices and envi-
ronments of the dedicated centers [8, 9].
To face these challenges, it is critical that the CIRT
treatments be reported similarly. Experts from IAEA
and the International Commission on Radiation Units
and measurements (ICRU) met in 2004 and 2006 to ad-
dress these issues and published dedicated proceedings
[10]. However, there is still no official recommendation.
The ULICE project
In this framework, ULICE was a FP7 project (part of
ENLIGHT) initiated in 2009 to address specific issues
such as particle radiobiology, intra-fractional moving tar-
gets, adaptive treatment planning, database organization
and gantry engineering [11]. In particular, ULICE-WP2
aimed to adapt joint concepts for dose volume and out-
come assessment, standard operating procedures for
clinical trial design and a clinical research infrastructure.
The objective of our study was to describe and com-
pare each stage of the treatment process in the existing
CIRT centers worldwide illustrated in a case of skull base
chordoma (SBC).
SBC is a rare and slow growing malignancy arising
from the remnants of the notochord, optimally man-
aged with surgery and postoperative radiation [12].
SBC is one of the most consolidated indications of
CIRT [13–17].
Methods
ULICE-WP2 included the following members: radi-
ation oncologists involved in CIRT either in treating
(n = 3) or in planned facilities (n = 6) or in ICRU (n =
1), physicists (n = 6), computer scientist expert in im-
aging (n = 1) or machine learning (n = 1), radiation
biologists (n = 2) and quality manager (n = 1). Based
on ten working parties, we produced a set of consen-
sual reports released to the European Commission
after a formal approval procedure involving the Steer-
ing Committee, the Technical Project Board and an
External Scientific Advisory Board [18–23].
We drafted a survey addressing the potential sources
of uncertainties altering clinical effects as far we may
hypothesize, based on ICRU and our own reports [4, 10,
19–28] (Table 1). The questionnaire was centrally
Table 1 Outline of the survey
∙ Institution/name
∙ Equipment
o type of accelerator,
o energy,
o beam delivery system,
∙ Treatment setup
o patient position: lying, sitting,
o immobilization, fixation device(s) used
o methods used to ensure positioning reproducibility
o methods used for recording patient positioning: XR, scan
o image fusion (if used): technique, recording
∙ Delineation procedure
o procedure for CTV(s) delineation
o safety margins added around the CTV to define the PTV and to
ensure its proper coverage
o do you proceed separately for each beam to add the above-
mentioned margins?
o procedure for dose prescription/specification to the CTV-PTV
o procedure for dose limitation/specification to OARs
∙ Beam delivery
o one single fixed beam
o several fixed beams
o scanning beam
∙ Dosimetry
o biological plan optimization
o beam dosimetry: calibration, homogeneity
∙ Procedure for control and validation of the treatment plan before
application to the first session
∙ What kind of record are stored at the end of the treatment?
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reviewed within the group and sent to the expert radi-
ation oncologist(s) involved in SBC management in the
10 CIRT facilities in operation by February 2017.
The responders had to consider the following clinical
case: a 50 y.o. man with a clival chordoma previously
operated with a macroscopic residual tumor (R2) and
eligible to one the following state-of-art CIRT schedules:
A) 45 Gy EQD in 3 Gy EQD/d, 5 days a week, 15 frac-
tions on the initial PTV (PTV1) including the GTV and
suspected subclinical disease – followed by a boost to a
cumulative dose of 63–66 Gy EQD in 3 Gy EQD/d, 5
days a week, by 6–7 additional fractions, on a restricted
PTV2 including the GTV visible on the MRI [29]
(Fig. 1).
B) 34.2–39.6 Gy EQD in 3.8–4.4 Gy EQD/d, 4 days a
week, 9 fractions on the PTV1 – followed by a boost to
a cumulative dose of 60.8–70.4 Gy EQD in 3.8–4.4 Gy
EQD/d, 4 days a week, by 7 additional fractions on the
PTV2 [30].
Results
We received 5 surveys from seven facilities representing
77% of the patients treated worldwide per November
2017 (16,704 pts. out of 21,675, Table 2A). HIT and MIT
use exactly the same equipment and procedures and we
distinguished HIMAC “old” and “new” facilities. We an-
alyzed the various hypothesized sources of uncertainties.
Native beam characterization
According to Table 2B, different equipment has been set
up in the successive facilities since 1994. In Japan, the
two synchrotrons of the pilot Heavy Ion Medical Accel-
erator in Chiba (HIMAC) produce ion beams from 4He
to 54Xe up to a maximum energy of 800MeV/u. PS was
first implemented with a beam-wobbling and ridge filter
delivery method. The same type of facility has been
reproduced in Hyogo, Gunma and Tosu, making the PS
delivery method the most widely used in the world so
far (Table 2). At the same time, GSI reproduced and im-
proved the ABS system originally outlined in the pioneer
facility in Berkeley - standardizing the raster scanning
delivery system in European then Chinese facilities.
More recently the new HIMAC facility implemented a
high dose rate ABS system incorporating superconduct-
ing technology, which offers fast 3D repainting as well
as a reduced gantry.
Anatomic data acquisition
Patient setup may interfere on intra/inter fraction tumor
motion and the related CTV-PTV margin to apply
(Table 2C).
Patient position
Patients are usually treated lying in supine position -
with rolling up to 20° when gantries are not available.
They can also be irradiated in prone or lateral position.
Immobilization device
In the Japanese centers, the patients are immobilized
with a 3 mm-thick non-perforated thermoplastic mask
over a MOLDCARE™ pillow. The mask is wrapped
around the patient-pillow-cradle block and fixed with
Fig. 1 Clinical case of a clival chordoma treated with CIRT; Primary + Boost plan 66Gy (EQD) in 22 Fx. Top panel: CT scan; Bottom panel: T2w MRI
(courtesy Dr. Uhl, HIT)
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straps. Vacuum bags are used to maintain the rest of the
body.
The German centers use preferentially 3-point soft
continuous thermoplastic masks with individual dental
splints and a set of standardized head supports.
CNAO resort to customized rigid non-perforated
thermoplastic-masks, mouth bites and head-rests or
moldable body pillows.
Simulation CT scan
All facilities acquire anatomic data with a CT scan with
(Japan, Germany) or without (CNAO) intravenous con-
trast. The CT slice thickness is less than 3mm. Houns-
field units from the simulation CT scan as well as from
the mask need to be converted in relative stopping pow-
ers to accurately define water equivalent tissue thickness
regarding the range of the particles.
Delineation
GTV definition - imaging - fusion
All the centers perform image fusion with MRI se-
quences and non-deformable algorithms based on ana-
tomical landmarks. Based on specific imaging findings,
axial T1 post gadolinium and T2 fat saturated or Flair
are mostly used to delineate SBC [31].
Procedure for CTV(s) delineation
Although the definition of the GTV appears consensual
between the participating centers, there are large varia-
tions in defining the CTVs and especially the low-risk
CTV (Table 2D). Subjective determinants such as clin-
ical experience come into account.
Target volumes may have several names according to
the institution; numbering can be misleading in relation
with the dose-level applied [29, 30, 32].
CTV-PTV margin
In the treatment of cranial lesions, the major source of
geometrical deviation is the relative motion of skin and
bone anatomy, significantly affecting the repositioning
accuracy [33–35]. In addition, the particle range vari-
ation is reported to be around 1mm, representing a fur-
ther source of systematic error [36].
Most facilities apply a 2–3 mm margin to define the
PTV according to two methods: i) isotropic expansion
around the related CTV; ii) portal-specific PTV.
Dose prescription
Treatment schedule
The two proposed treatment schedules are reported
among the active facilities (Table 2E) [29, 30].
CNAO applies the most hypofractionated dose sched-
ule by default (B); however, whenever the PTV cannot
be properly covered, schedule (A) is applied.
Dose specification
The European and Japanese teams apply different units
and different formulae to specify and calculate equieffec-
tive dose (EQD) in relation with their radiobiological
modelling.
In Mizoe et al. report, EQD (named “clinical dose”)
was expressed in photon-equivalent doses (gray equiva-
lent dose [GyE]). Planning aims to cover the PTV with
at least 90% of the prescribed dose [30].
In the HIT-1 protocol, EQD is expressed in GyE.
Noteworthy, GSI reported the dose in CGE (cobalt gray
equivalent) as well as in Mizoe review [14, 30].
At GSI/HIT/MIT, EQD is rather specified to each scan
spot covering the PTV. Throughout the dose distribu-
tion, at least 90% of the prescribed dose aims to cover
more than 95% of the PTV unless OAR constraints limit
the dose. Hot and cold spots never exceed the maximum
diameter of 15 mm [10].
In its ULICE-report, CNAO specified dose in Gy
[RBE] [32].
Biological modeling
At NIRS, the calculation of “clinical dose” is based on the
relationships between RBE and LET of human salivary
gland tumor (HSG) cells for flattening the SOBP and on
the clinical experience with fast neutrons. The RBE of car-
bon ions is assumed to be 3.0 at the distal region of SOBP
[37]. This method was implemented in the initial HiPLAN
treatment planning system (TPS) and disseminated to the
other Japanese centers [38]. With the implementation of
the active scanning delivery method at the NIRS new facil-
ity, the modified microdosimetric kinetic model (MKM)
was integrated into a novel TPS [39].
In Europe, the RBE is determined for each single spot
through the local effect model (LEM) which assumes
that equal local energy deposit should lead to equal local
effects in the cell nucleus, independently of the radiation
quality [40].
Dose constraints on OAR
Dose constraints applied to OAR are summarized in
Table 2E.
At HIT-MIT, equivalent EQD in 2Gy fractions are re-
trieved to cope with the corresponding QUANTEC rec-
ommendations for optic structures as well as brain stem
surface, assuming alpha/beta values of 2Gy.
Treatment planning
Treatment planning system
Overall, there are no major differences on the basic
functionalities of the TPS (Table 2F).
The Japanese centers are equipped with XiO-N
(ELEKTA, Stockholm, Sweden and Mitsubishi Electric,
Tokyo, Japan) with a divergent pencil beam method
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algorithm based on the modified MKM EQD calculation
model since 2012.
In the European centers, the inverse TPS - Syngo RT
Planning (Siemens, Erlangen, Germany) is presently
used. Syngo RT Planning includes a detailed radiobio-
logical modelling of the effects of high LET radiation
based on the LEM model and adopts pencil beam algo-
rithms too.
Noteworthy, CNAO recently equipped with the Carbon
Planning module on Ray Station (RaySearch Laboratories
AB, Sweden) - including modules for carbon pencil beam
scanning with robust biological optimization (using both
the MKM and LEM models).
Dose delivery
Two delivery systems
The narrow pristine peak produced by the accelerator
cannot be used directly so that the beam delivery system
is of prime importance. Two strategies have been ap-
plied: PS and ABS [41](Table 2G).
Since the beginning of this decade, most CIRT facil-
ities have adopted the latter in order to limit the reduc-
tion of the beam fluence and fragmentation. Among the
participating centers, HIMAC pilot facility and Gunma
still use PS.
Beam geometry
In PS, beam parameters such as MLC positions, SOBP
size, range shifter thickness, range compensator shape,
etc. are adapted to satisfy the tolerance doses for OARs.
With ABS, treatment planning is either possible by
single field uniform dose optimization (SFUD) or by
multiple field optimization (IMPT, Intensity Modulated
Particle Therapy). Two to four irradiation fields are
chosen at HIT-MIT.
Methods to ensure positioning reproducibility
Positioning accuracy is controlled using orthogonal
x-rays or cone-beam-CTs. Set-up deviations are cor-
rected prior to irradiation by correction with the vector
of the robotic table. A 6 degrees-of-freedom correction
is permitted in the most advanced facilities.
In CNAO optical tracking and in-room imaging sys-
tems are integrated [42].
Discussion and suggestions from ULICE WP2
Van Herk reviewed the most common uncertainties af-
fecting dose distribution in external beam radiotherapy
(EBRT) [43]. Particle therapy raises additional issues and
uncertainties in dose deposition mainly linked to the fi-
nite range as demonstrated in protontherapy [44].
Analyzing the whole CIRT planning process in the
participating centers, we pointed out the singularity of
the facilities and beam delivery systems, a divergent def-
inition of target volumes, the multiplicity of TPS and
EQD calculation approximations. Our multidisciplinary
working group proposed the following counter-measures
addressing the improvable limitations.
Beam production and delivery
Differences in equipment between centers may influence
the components of the physical dose at the patient’s
entrance.
It appears possible to accurately measure the physical
dose and its composition in terms of individual particle
energy, direction and LET spectrum at the exit of the de-
livery system. Such parameters in addition to their
spatial distribution in relation with cross-section anat-
omy could be stored to feed more robust modeling sys-
tems in the future.
Immobilization and anatomic data acquisition
devices and the CIRT beam has to be emphasized as re-
ported in our clinical model [45, 46]. Although they can-
not easily be standardized, positioning systems and
anatomic data acquisition (contrast medium use) must
be perfectly described in the trial protocol as this could
affect particle range calculation.
Target volume definition and delineation
The GTV and CTV are oncological volumes defined
in the dedicated ICRU Reports [4, 24–28]. Contrarily
to GTV, CTV delineation varies substantially between
the centers. We could hold a joint symposium to
adopt consensus delineation guidelines with standard-
ized imaging procedures as performed in other tumor
locations [47] - keeping in mind the natural history
of the disease [48, 49].
Conversely to EBRT, adding internal and set-up mar-
gins quadratically to construct PTV [4] appears inad-
equate in CIRT since depth margins are to be
incorporated to account for range uncertainties in
addition to the typical lateral geometric uncertainties.
When using a single beam, the different margins could
theoretically combined as an anisotropic shell around
the CTV [50]. Portal-specific PTV should be theoretic-
ally employed in PS. However, when two (or more)
non-parallel opposed particle beams are applied, delinea-
tion of a (unique) PTV would generate complex compu-
tation issues for the TPS [26]. ABS raise additional
issues. The dose is not prescribed to a reference point
but to each voxel. Moreover, organ motion, artificial ma-
terial and tissue heterogeneities may have a strong im-
pact on dose distribution [51, 52]. Overall, specific
attention and complex irradiation techniques such as
gating, repainting and tracking are needed to alleviate
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the motion effect in CIRT although this factor is not in
the foreground in SBC [53–55].
Dose specification and calculation
The ICRU recommends that the absorbed dose distri-
bution (3D) be systematically reported, to allow inter-
pretation of the effects and to reconstruct the
irradiation conditions if needed [27, 56]. However,
specification of these quantities alone is not usually
sufficient to predict biological effects when comparing
treatments in different conditions. In CIRT the par-
ticle energy spectrum varies along the ion path within
the treated volume. Each voxel receives a mixed field
of particles of different LET and nature due to frag-
mentation, so the same physical dose at a given point
may correspond to different particle spectra, each of
which could lead to a particular biological and clinical
effect [57].
Despite different specifications, EQD should be re-
ported in addition to absorbed dose [10, 57–59].
These two quantities are expressed in Gy. In order
to avoid confusion, the symbol for EQD should be
written “D (EQD)” with a space between “D” and
“EQD”.
EQD is the product of absorbed dose and a trans-
formation function (no dimension) which includes all
the factors that influence the biological/medical ef-
fect(s) – including RBE [19] (Fig. 2). It is likely that
the transformation functions are distinct between the
centers and their determinants need thus to be
reported.
In addition the calculation of EQD is not equivalent
between the active facilities and comparing different
TPS is a very difficult task in CIRT due to the many in-
terconnected components and the different biological
models [60].
Each individual TPS generate dose calculation un-
certainties as soon the beam penetrates into the pa-
tient due to the modeling of mixed radiation field
and tissue heterogeneities [61] (Fig. 3). Monte Carlo
simulations are probably the most accurate and reli-
able to estimate those uncertainties [62]. NIRS esti-
mated that EQDs produced at NIRS and GSI are
biologically identical using HSG and in vivo assays
[63]. CNAO thus recalculated their treatment plans -
minimizing differences in physical dose distributions
between the two treatment plans. FLUKA has been
interfaced with LEM I to retrieve physical doses.
Overall, the NIRS model estimates a lower RBE of
carbon ions when compared to LEM. They proposed
conversion tables to minimize the physical dose varia-
tions in the PTV [64–66].
Alternative models particularly in the domain of nano-
and microdosimetry could apply [67]. A model-inde-
pendent interface for RBE predictions is being
implemented [68].
So far, research in treatment planning of CIRT is usu-
ally based on a fixed RBE or α/β value. Since
Fig. 2 Uncertainties affecting dose deposition throughout CIRT treatment planning process
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fractionation regimens differ from 3D-CRT, α/β ratios
for dose-limiting toxicity and the specific tumor cell type
are expected to differ substantially [69]. Radiobiological
data for both human tumors and healthy tissues are in-
complete. Ideally, prospective experiments should be
performed. Overlapping of PTV and OAR raises add-
itional issues [70].
Quality assurance procedures
Each center has developed its own quality assurance
procedures based on local equipment and the avail-
able “homemade” measuring tools. When inter-
national clinical trials will be initiated, it will be
critical to have a uniform quality assurance
procedure.
ICRU/IAEA Committee Report 76 - which some of
the members of our committee belonged to - proposed
recommendations for harmonized dosimetry guidelines
and accurate beam calibration [71].
Thereupon, ETOILE is the first transnational pro-
spective randomized trial comparing definitive carbon
ion therapy versus photon or combined photon and
protontherapy as standard treatment for unresectable
or macroscopically uncompleted resected radioresis-
tant tumors. Eligible tumors are axial chordoma (ex-
cept of base of skull), adenoid cystic carcinoma of
head and neck (except of trachea) and sarcomas of
any site (except chondrosarcoma of the skull base),
non-previously irradiated and without pre-planned
surgery or chemotherapy after the clinical trial pro-
cedure. Randomization is balanced 1 for 1. Patients
of the experimental arm are treated in carbon ions
centers in Europe and patients of the standard arm
are treated in France in their closest participating
radiotherapy center. An accrual of 250 patients is
needed and an absolute difference of 20% of relapse
free survival at five years is awaited. The main end-
point is the progression free survival at five years
(ClinicalTrials.gov Identifier: NCT02838602) We ap-
plied the aforementioned proposals when we drafted
the protocol [72].
Conclusion
Multiple uncertainties affect EQD definition, depos-
ition and calculation in CIRT. Although it is not pos-
sible to harmonize all the steps of the treatment
planning between the active centers, we proposed
some of the following suggestions in order to further
pool the results in the frame of international trials.
Reporting only EQD appears clearly insufficient. Reg-
istering and storing raw individual particle number,
energy and direction prior entry into the patient and
Fig. 3 Transformation of absorbed dose D to equieffective dose applicable to all types of radiation therapy techniques. The concept of EQD
includes the combined effects of recovery capacity and recovery kinetics
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LET in each voxel (for all fragments) according to the
simulation CT scan, could allow for centralized EQD
reconstruction with existing or novel radiobiological
models. On the other hand, it is theoretically possible
to standardize the definition and delineation of
structures.
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